Compounds isolated from antrodia cinnamomea and use thereof

ABSTRACT

The present invention relates to novel compounds from  Antrodia cinnamomea  and their use.

FIELD OF THE INVENTION

The present invention is related to a compound from the metabolite of Antrodin C isolated form Antrodia cinnamomea.

BACKGROUND OF THE INVENTION

Antrodia cinnamomea (Polyporaceae, Aphyllophorales) is well known in Taiwan as a traditional Chinese medicine. It grows only on the inner heartwood wall of the endemic evergreen Cinnamomun kanehirai (Hey)(Lauraceae) in Taiwan. It has been used as treating food to remedy toxication, diarrhea, abdominal pain, hypertension, itchy skin, and liver cancer (Tsai Z T, et al. 1982 Sheng-Yun Publisher Inc.: Taichung, Taiwan, pp 116-117). The compounds of steroid acid (Chen C H, et al. 1995 J Nat Prod 58: 1655-1661; Yang S W, et al. 1996 Phytochemistry 41: 1389-1392), triterpenoids (Cherng I H, et al, 1995 J Nat Prod 58: 365-371; Cherng I W, et al. 1996 Phytochemistry 41: 263-267), diterpenes (Chen C C, et al. 2006 J Nat Prod 69: 689-691), sesquiterpene lactone (Chiang H C, et al. 1995 Phytochemistry, 39, 613-616) and phenyl and biphenyl (Chiang H C, et al. 1995 Phytochemistry, 39, 613-616; Huang K F, et al. 2001 Chin Pherm J 53: 327-331) were isolated from the fruiting body of Antrodia cinnamomea, possessing cytotoxic, neuroprotective, anti-inflammatory, apoptotic activities. Moreover, mycelium, another part of Antrodia cinnamomea has antioxidative (Hsiao G., et al. 2003 J Agric Food Chem 51: 3302-3308; Song T Y, et al. 2003 J Agric Food Chem 51: 1571-1577), hepatoprotective (Han H F, et al. 2006 Chem Pharm Bull 54: 496-500), anti-inflammatory (Shen Y C, et al. 2004 Planta Medica 70: 310-314; Hseu Y C, et al. 2005 Int Immunopharmacol 5: 1914-1925), anti-hepatitis B virus (Lee I H, et al. 2002 FEMS Microbiol Lett 209: 63-67), vasorelaxation (Wang G. J, et al. 2003 Life Sci 73: 2769-2783) and apoptosis (Song T Y, et al. 2005 J Agric Food Chem 53: 5559-5564) actions.

SUMMARY OF INVENTION

The present invention provide a compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁-₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl.

The present invention also provides a composition comprising a compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 HMBC (a) and NOE (b) Correlations of M1.

FIG. 2 HMBC Correlations of M2 and M3.

FIG. 3 TIC of feces (a), bile (b) and plasma(c) sample after oral administration of Antrodin C at the dose of 50 mg/kg.

FIG. 4 MS spectra (negative mode) of M1-M5 and Antrodin C in the rat feces, bile and plasma samples.

FIG. 5 The structures of Antrodin C and its metabolites.

FIG. 6 Concentration-time curve of M1 in bile samples after I.V. Antrocin C at the dose of 10 mg/kg (a) and P.O. 50 mg/kg (b).

FIG. 7 The TIC of Bile and Plasma and the UV Spectra of Faeces after Administration of Antrodin C in Rats

FIG. 8 The UV spectra of the blank plasma samples and the plasma samples after i.v. of M1

DETAIL DESCRIPTION OF THE INVENTION

In this invention, three maleic acid and two succinic acid derivatives (Antrodin A-E) were firstly isolated from the mycelium of Antrodia cinnamomea, and the cytotoxic activity against LLC cells of Antrodin C and B were confirmed (Nakamura N, et al. 2004 J Nat Prod 7: 46-48). Furthermore, Antrodin C, with the highest amounts in mycelium, exhibited protective effect against hepatitis model induced by LPS. Whereas the metabolism study on the compounds of Antrodia cinnamomea were never reported. In the present invention, the metabolites of Antrodin C in the rat bile and feces samples were identified by LC/MS-MS with electrospary ionization (ESI), and the pharmacokinetics of M1 in rat bile was performed after oral administration (50 mg/kg) and intravenous injection (10 mg/kg) of Antrodin C by PAD-HPLC.

The present invention provides a compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl.

R₁ or R₂ of the compound is C₁₋₆ carboxylic acid. In the preferred embodiment, R₁ or R₂ is COOH, R₃ is C₁₋₆ alkyl and R₄ is isobutyl. In the more preferred embodiment, the compound is (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid, (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 4-methyl ester or (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 1-methyl ester.

The compounds are metabolites of Antrodin C in rats, and the Antrodin C is isolated from the myvelium Antrodia cinnamomea.

The present invention provides a composition comprising a compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl.

In the preferred embodiment, the compound is (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid, (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 4-methyl ester or (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 1-methyl ester.

The present invention provides the compounds have possessing antioxidation, antimicrobial, antibacterial actions, AChE inhibitory activity, antispasmodic or vasorelaxant activities.

The compound of the invention can decrease systolic blood pressure or increase high density lipoprotein. In addition, the same compound has central cholinergic agonism, hepatoprotection, anti-inflammation or anti-tumor activity. Especially, the compound of the invention can inhibit tumor from the cells or tissues selected from the group consisting of liver, lung, intestine, bone, blood, lymph and breast. The subject accepting the mixture of the invention includes but is not limited to human, mammal, mouse, rat, horse, pig, chicken, duck, dog and cat.

The present invention also provides a composition, which comprises the compound of the invention. The composition of the invention can decrease systolic blood pressure or increase high density lipoprotein. In addition, the composition of the invention has central cholinergic agonism, hepatoprotection, anti-inflammation or anti-tumor activity. Especially, the compound of the invention can inhibit tumor from the cells or tissues selected from the group consisting of liver, lung, intestine, bone, blood, lymph and breast. The subject accepting the mixture of the invention includes but is not limited to human, mammal, mouse, rat, horse, pig, chicken, duck, dog and cat.

Example

Chemicals and Reagents

General anaerobic medium (GAM) broth was purchased from Nissui Co. (Tokyo, Japan). Liquid chromatographic grade solvents, trietylamine, 4-dimethylaminopyridine (4-DMAP), silica gel BW-820MH (Fuji Silysia), ODS DM 1020T (Fuji Silysia) for open column chromatography, Merck precoated Silica gel 60F₂₅₄ (0.25 mm) and Merck RP-18F₂₅₄ (0.25 mm) for TLC analysis were obtained from Wako Pure Chemical Industries Ltd. (Osaka, Japan).

Instruments

Compounds were analyzed by ¹H- and ¹³C-NMR and 2D NMR using a Unity Plus 500 (varian) NMR spectrometer with tetramethylsilane as an internal standard, and chemical shifts are shown as 6 values. Intestinal bacteria were anaerobically incubated using an EAN-140 (Tabai Co., Osaka, Japan). The HPLC instrument was an Agilent 1100 system (Agilent Technologies, Waldbronn, Germany) comprising an Agilent 1100 series binary pump with a photodiode array detector (PAD) and a series 7725i injector with a 20 μl loop. Data were acquired and integrated using a ChemStation. The HPLC system was connected to an Esquire 3000^(plus) mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany) equipped with an ESI source. All LC/MS-MS data were acquired using Esquire Control software and analyzed using software from by Bruker Daltonics.

Example 1

Synthesis of M1-M3

Antrodin C (50 mg) was dissolved in 5 ml water, and 1N KOH (0.5 ml) was added stirring for 5 min. 1N HCl was used to adjust PH to 8. After filtration, the solution kept under room temperature overnight. After filtration again, the supernatant was lyophilized, and reconstitute by some MeOH, and then filtered and evaporated in vacuo., yield of M1 was 13 mg (26%).

The ¹H and ¹³C-NMR spectra of M1 (Table 1) was very similar to those of Antrodin C and showed the presence of isobutyl moiety, a 3-methyl-2-butenyloxy moiety, and a para-substituted benzene ring, which supported by ¹H-¹H COSY-HMQC experiments. But carbonyl carbon (δ 178.9:1), methylene carbon (δ39.7:1′), proton (δ1.87:1′) and methyne proton (δ1.56:2′) of isobutyl moiety, benzene carbon conjugated olefine (δ131.6:1″) and benzene proton next to that (δ7.11:2″, 6″) were different from those of Antrodin C, these all the carbon of M1 were downfield shifted than those of Antrodin C and these all the proton of M1 were upfield shifted than those of Antrodin C. In the HMBC experiments, long-range correlations were observed as shown in FIG. 1( a). We decided that Olefine coupling (2-C and 3-C) of M1 is Z because NOE was observed between 1′-H and 3′4′-H or 6″-H in the NOESY spectrum of M1 (FIG. 1( b)). According to these results, M1 was defined as (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]-phenyl}but-2-enedioic acid. Anhydride M4 (Antrodin A) and dicarboxylic acid M1 were converted each other by acid and base condition.

Antrodin A (500 mg) was dissolved in 1 ml MeOH, and trietylamine (0.2 ml, 1.6 mmol) and 4-dimethylaminopyridine (4-DMAP, 13.4 mg, 0.11 mmol) were added to the solution stirring for 20 h at 25° C. And then the mixture was chromatographed by a open ODS column eluting with methanol and water (30:70→100:0), the fraction containing M2 and M3 were evaporated in vacuo, and then analyzed by NMR and LC/MS. The data of ¹H-NMR and ¹³C-NMR of M1-M3 were showed in Table1, 2.

The ¹H and ¹³C-NMR spectra of M2 and M3 were also similar to those of M1 except for methoxy groups and showed the presence of isobutyl moiety, a 3-methyl-2-butenyloxy moiety, and a para-substituted benzene ring. In the HMBC experiments, methylene proton of isobutyl moiety (δ2.16:1′) and carbonyl carbon (δ174.0:1) of M2 showed long-range correlation, and methylene proton of isobutyl moiety (δ2.14:1′) and carbonyl carbon (δ171.4:1) of M3 showed long-range correlation (FIG. 2). The structure of M2 and M3 were defined as (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 4-ester and (2Z)-2-isobutyl-3-{4-(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 1-methyl ester, respectively.

TABLE 1 ¹H-NMR Spectral Data of M1 (D₂O), M2 and M3 (CD₃OD) (δ ppm, J = Hz) M1 M2 M3 1′ 1.87 (2H, d, J = 6.5) 2.16 (2H, d, J = 7.0) 2.14 (2H, d, J = 7.0) 2′ 1.56 (1H, m) 1.69 (1H, m) 1.69 (1H, m) 3′, 4′ 0.72 (6H, d, J = 6.5) 0.81 (6H, d, J = 7.0) 0.80 (6H, d, J = 6.5) 2″, 6″ 7.11 (2H, d, J = 8.5) 7.14 (2H, d, J = 9.0) 7.20 (2H, d, J = 9.0) 3″, 5″ 6.88 (2H, d, J = 8.5) 6.91 (2H, d, J = 9.0) 6.91 (2H, d, J = 9.0) 1″′ 4.50 (2H, d, J = 6.5) 4.54 (2H, d, J = 6.5) 4.54 (2H, d, J = 6.5) 2″′ 5.41 (1H, brs) 5.46 (1H, m) 5.46 (1H, m) 4″′ 1.68 (3H, s) 1.77 (3H, s) 1.77 (3H, s) 5″′ 1.64 (3H, s) 1.75 (3H, s) 1.75 (3H, s) —OMe — 3.82 (3H, s) 3.72 (3H, s)

TABLE 2 ¹³C-NMR Spectral Data of M1 (D₂O), M2 and M3 (CD₃OD) (δ ppm) M1 M2 M3 1 178.9 174.0* 171.4* 2 140.3 144.0 134.3 3 137.5 136.3 145.4 4 166.1 * * 1′ 39.7 40.0 40.0 2′ 27.2 29.0 29.0 3′, 4′ 22.2 22.8 22.8 1″ 131.6 128.5 128.5 2″, 6″ 130.5 131.4 131.0 3″, 5″ 114.8 115.5 115.5 4″ 157.0 160.0 160.0 1″′ 65.3 65.9 65.9 2″′ 118.4 121.1 121.1 3″′ 141.6 138.7 138.7 4″′ 25.1 25.9 25.9 5″′ 17.3 18.2 18.2 —OMe — ** **

Example 2

Treatment of animals

Male Wistar rats (9 weeks old) purchased from SLC Co. (Hamamastu, Japan), were fed with standard laboratory chow for one week, fasted overnight and given free access to water before drug administration. Urine and feces samples were collected while the rats remained isolated in metabolic cages. The animals were light anesthetized with diethyl ether during surgical procedures. Bile samples (n=5) was collected by cannulating a polyethylene tube (PE-10) into the rat bile duct at intervals of 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36 and 48 h after oral (50 mg/kg) and intravenous (10 mg/kg) administration of Antrodin C. The blood sample was collected from the inferior vena cava using a heparinized injector when the abdomen was exposed by a midline abdominal incision after administration. The blood samples were centrifuged at 8000×g for 15 min to separate the plasma, and then all samples were stored at −20° C. for later analysis.

Sample Preparation for Analysis

Thawed urine and bile samples (0.5 ml) dissolved in 3 volumes of acetonitrile, and then centrifuged at 8000×g for 15 min. The supernatant was passed through a 0.45 μm Millipore syringe filter (Nihon Millipore, Tokyo, Japan) for LC/MS-MS analysis. Plasma samples were passed through Solid Phase Extraction cartridges (Waters Co., Milford, U.S.A.) that had been washed with 3 ml of acetonitrile and equilibrated with 6 ml of water. The constituents were eluted with 2-3 ml of acetonitrile from the cartridge, then the eluate was evaporated under a stream of nitrogen at 35° C. to leave a residue that was dissolved in 100 μl of acetonitrile for LC/MS-MS analysis. The bile samples for pharmacokinetic study, which containing M2, M3 and M4 were diluted by same volume water, and then incubated in 37 ° C. bath for 12 h, the M2-M4 would thoroughly converted to M1. After treating the bile sample as described above, the amount of M1 was calculated by PAD-HPLC.

Identification of Metabolites in Rat feces, Bile and Plasma

The metabolites in feces, bile and plasma were analyzed by LC/MS-MS. The LC/MS-MS equipment comprised a column containing TSK gel ODS-80 Ts (particle size, 5 μm; 4.6×150 mm i.d., Tosoh Co., Tokyo, Japan). Samples were eluted through the column with 0.1% AcOH and acetonitrile (35:65) at a flow rate of 1 ml/min at 30° C. The standard negative ion mode was selected under the following conditions: full scan range, 50-800 m/z; scan resolution, 13000 m/z/sec; nebulizer, 50.0 psi; dry gas, 10.0 l/min; dry temperature, 360° C. Full scanning in the region of m/z 50 to 600 assigned several peaks to Antrodin C and the metabolites in the TLC when compared with those of blank samples (FIG. 3). The MS spectra revealed intense ion peaks at m/z 331, 345, 345, 313, 312 and 328 [M-H]³¹ as M1, M2, M3, M4, M5 and Antrodin C, respectively (FIG. 4, Table 3). In the feces, metabolites were M1-M3, M5 with original Antrodin C; in the bile were M2-4; and in the plasma were M1 with another unknown peak. There was neither metabolite nor Antrodin C in the urine sample. Comparing to standard materials and synthesized compounds, the peak in the MS profile at m/z 328 [M-H]⁻ with retention time (t_(R))=8.2 min was derived from Antrodin C (MW 329), and M1 (m/z 331 [M-H]⁻, t_(R)=4.4 min) was dicarboxylic acid by hydrolysis of Antrodin C; M2 and M3 (m/z 345 [M-H]⁻, t_(R)=7.7 and 8.4 min), which were 14 larger than those of M1, were two kinds of monomethyl esters of M1; M4 (m/z 313 [M-H]⁻, t_(R)=21.6 min) was Antrodin A and M5 (m/z 312 [M-H]⁻, t_(R)=11.5 min) was Antrodin B. The structures of Antrodin C and its metabolites were shown in FIG. 5.

TABLE 3 Retention time (t_(R)) and MS spectra of Antrodin C and its metabolites t_(R) MS spectra (Negative mode) Antrodin C 8.2 328, 259, 242, 216 M1 4.4 331, 287, 218, 132 M2, M3 7.7, 8.4 345, 313, 244, 232, 189 M4 21.6 313, 244 M5 11.5 312, 243, 200 Unknown metabolite 10.8 319, 301, 257, 179, 163, 135

Metabolism of Antrodin C and Metabolites by Intestinal Bacteria In Vitro

Mixtures of rat (RIB) or human (HIB) intestinal bacteria (5 g each) prepared as described (Xie L H, et al. 2003 Biol Pharm Bull 51: 378-384), together with Antrodin C (5 mg) dissolved in Tween 20 (0.5 ml), M1 (5 mg) dissolved in water (1.0 ml) or rat bile samples (10 ml) with metabolites M2-M4, which were collected after oral administration of Antrodin C, were added to GAM broth (50 ml), and anaerobically incubated at 37° C. for 3 d. The incubation mixture was extracted with 3 volumes of acetonitrile, and then passed through a 0.45 μm filter. Then, Antrodin C was converted to M5 (Antrodin B). Moreover, the metabolites (M2-M4) in bile samples, which were collected after oral administration of Antrodin C in rats, could absolutely transferred to M1 after 30 min incubation. Whereas M1 was not metabolized by intestinal bacteria flora, although prolonged the incubation time to 3 d.

Validation of M1 by PAD-HPLC

Linearity: M1 was dissolved in rat blank bile to prepare seven dilutions of standard solutions. Response linearity was determined for the seven concentrations after three injections for each level. The limit of detection (LOD) of the method for each constituent was established when the signal to noise ratio (S/N) was 5.

Accuracy: Intra- and inter-assay variability was determined by analyzing high, medium and low standard concentrations of rat bile five times on the same day and continuously for 5 d, respectively.

Recovery: Two standard concentrations were mixed with rat bile samples after the oral administration of Antrodin C with a known amount of M1, and recovery rates of the added amounts were calculated.

Stability: Three concentrations of bile samples that had been prepared for PAD-HPLC analysis were placed at room temperature for 12 h, or in a refrigerator at 4° C. for 1, 3 and 5 d. The average peak areas of constituents in the samples and relative standard deviation (RSD) were calculated.

Validation of PAD-HPLC Quantitation

The regression equation of M1 in rat bile sample was Y=610.22X−3.94; γ=0.9998; and the linearity range was 0.05-2.0 μg/ml. Intra-day and inter-day (n=5) variations of M1 in rat bile samples were shown in Table 4. The CV did not exceed 6%, and the accuracy rates were all within 85-110%. CV values of recovery rates were shown in Table 5, which were less than 10% at low and high concentrations with recovery rates of 93.4 and 99.6%. The stability test showed that relative standard deviation remained within 5% under all the conditions; therefore, the samples were stable during the test. Thus, the accuracy, recovery, and stability tests met the criteria for quantitative determinations in bile samples.

TABLE 4 Intraday and Interday (n = 5) Variations of M1 in Rat Bile Added (μg) Found (μg) Accuracy (%) CV (%) Intraday 0.05 0.0456 ± 0.0018 91.2 3.9 0.5 0.533 ± 0.008 106.6 1.5 2.0 1.99 ± 0.04 99.5 2.0 Interday 0.05 0.0438 ± 0.0026 87.6 5.9 0.5 0.443 ± 0.009 88.6 2.0 2.0 1.98 ± 0.06 99.0 3.0

TABLE 5 Recovery of M1 in Rat Bile Added (μg) Found (μg) Recovery (%) CV (%) 0.05 0.0467 ± 0.0045 93.4 9.6 0.5 0.498 ± 0.020 99.6 4.0

Pharmacokinetics of M1 in Rat Bile

The concentration-time data in rat bile (n=5) were computer fitted using a program of Pharmacokineitics 3p97 edited by the Mathematics Pharmacological Committee, Chinese Pharmacological Society. The following pharmacokinetic parameters were obtained: half-time of absorption phase (t_(1/2 (Kα))) and half-time of elimination phase (t_(1/2 (Kβ))) in the bile samples after oral administration of Antrodin C at the dose of 50 mg/kg. The area under the concentration-time curve (AUC_((iv)) and AUC_((p.o.))) was calculated by the statistical moment method of non-compartmental pharmacokinetic analysis. And then clearance (Cl_(m, b)) and absolute bioavailability (F_(m, b)) were calculated by the equations as following: Cl_(m, b) (ml/h·kg)=Dose _((i.v.))/AUC _((i.v.)) and F_(m, b) (%)=AUC _((p.o.))·Dose_((i.v.))/[AUC _((i.v.))·Dose _((p.o))]. Data were expressed mean and standard deviation (S.D.) for each group.

The concentrations of M1 in bile samples were calculated after P.O. administration of 50 mg/kg and I.V. 10 mg/kg of Antrodin C. The concentration-time curves of M1 were shown in FIG. 6. The pharmacokinetic parameters were shown in Table 6. After oral administration, t_(1/2 (kα)) and t_(1/2 (kβ)) were 0.95 h and 12.64 h, respectively. AUC_(0-lim) were 1.61 (P.O.) and 1.68 h mg/ml (I.V.), Cl_(m.b). was 5.96 ml/h·kg and F_(m.b.) was 19.43(%). Accumulated excretion ratio of Antrodin C were 5.46±1.62% (P.O.) and 56.85±13.40 (I.V.). Therefore, Antrodin C was very quickly not only absorbed from gastrointestine, but also metabolized in the liver. The mainly excretion was bile-feces pathway in rats.

TABLE 6 Pharmacokinetic parameters of M1 in rat bile samples after P.O. and I.V. of Antrodin C I.V. (10 mg/kg) P.O. (50 mg/kg) Cl_(m.b.) t_(1/2 (kα)) t_(1/2 (kβ)) AUC_(0-lim) AUC_(0-lim) (ml/ F_(m.b.) (h) (h) (h mg/ml) (h mg/ml) h kg) (%) 0.95 ± 0.07 12.64 ± 2.24 1.61 ± 0.58 1.68 ± 0.31 5.96 19.43

Example 3

Repeat example 2, results are shown in FIG. 7 and FIG. 8 

1. A compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₂₋₁₀ alkyl, C₂₋₁₀ alkenyl or, C₂₋₁₀ alkynyl.
 2. The compound of claim 1, wherein R₁ or R₂ is C₁₋₆ carboxylic acid.
 3. The compound of claim 1, wherein R₁ or R₂ is COOH.
 4. The compound of claim 1, wherein R₃ is C₁₋₆ alkyl.
 5. The compound of claim 1, wherein R₄ is isobutyl.
 6. The compound of claim 1, which is (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid. (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 4-methyl ester or (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 1-methyl ester.
 7. The compound of claim 6, wherein the compound is metabolites of Antrodin C in rats.
 8. The compounds of claim 7, wherein the Antrodin C is isolated from the mycelium of Antrodia cinnamomea.
 9. A composition comprising a compound having the formula

wherein R₁ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₂ is C₁₋₁₀ carboxylic acid or C₁₋₁₀ ester; R₃ is H, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl or C₂₋₁₀ alkynyl; and R₄ is H, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or isobutyl.
 10. The composition of claim 9, wherein the compound is (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid, (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 4-methyl ester or (2Z)-2-isobutyl-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}but-2-enedioic acid 1-methyl ester.
 11. The composition of claim 9, wherein compounds have possessing antioxidation, antimicrobial, antibacterial actions, AChE inhibitory activity, antispasmodic or vasorelaxant activities.
 12. The composition of claim 9, which decreases systolic blood pressure or increases high density lipoprotein.
 13. The composition of claim 9, which has central cholinergic agonism, hepatoprotection, anti-inflammation or anti-tumor activity.
 14. The composition of claim 12, wherein tumor is from the cells or tissues selected from the group consisting of liver, intestine, bone, blood, lymph and breast. 